Document Detail

SCH 34826: an overview of its profile as a neutral endopeptidase inhibitor and ANF potentiator.
MedLine Citation:
PMID:  1835684     Owner:  NLM     Status:  MEDLINE    
Our studies with the prototypical NEP inhibitor SCH 34826 indicate the potential role of this class of compounds in cardiovascular modulation. The data assembled to date indicate that NEP inhibition elicits significant ANF-like effects in animals and man. The early data generated to date on SCH 34826, when considered with those data generated on other NEP inhibitors, indicate that NEP inhibition may have therapeutic utility in some forms of hypertension and congestive heart failure.
E J Sybertz
Related Documents :
6163004 - Evidence for participation of kinins in the antihypertensive effect of converting enzym...
9695724 - Differential responses of the heart and vasculature to chronic blood pressure reduction...
12494284 - Captopril treatment reverses erectile dysfunction in male stroke prone spontaneously hy...
1657084 - Differences in first dose response to angiotensin converting enzyme inhibition in conge...
11086774 - Resuscitation of severe thermal injury with hypertonic saline dextran: effects on perip...
9025814 - Effects of head down tilt on hemodynamics, fluid volumes, and plasma na-k pump inhibito...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical nephrology     Volume:  36     ISSN:  0301-0430     ISO Abbreviation:  Clin. Nephrol.     Publication Date:  1991 Oct 
Date Detail:
Created Date:  1992-01-09     Completed Date:  1992-01-09     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0364441     Medline TA:  Clin Nephrol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  187-91     Citation Subset:  IM    
Schering Plough Research, Bloomfield, New Jersey 07003.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / pharmacology*
Atrial Natriuretic Factor*
Dioxolanes / pharmacology*
Dipeptides / pharmacology*
Drug Synergism
Heart Failure / drug therapy
Hypertension / drug therapy
Neprilysin / antagonists & inhibitors*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Dioxolanes; 0/Dipeptides; 0/Prodrugs; 105262-04-2/Sch 34826; 83861-02-3/SCH 32615; 85637-73-6/Atrial Natriuretic Factor; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The heart in hypertension.
Next Document:  Atrial natriuretic factor after cardiac surgery with cardiopulmonary bypass in children.